Flagship Pioneering, which has founded over 100 bioplatform companies, introduced the latest, Mirai Bio, during the BioProcess International Conference in Boston. Mirai, whose founding CEO is Geoffrey von Maltzahn, PhD, features an open end-to-end platform to enable the co-creation of fully optimized genetic medicines, according to Hari Pujar, PhD, founding president of Mirai and operating partner at Flagship Pioneering who spoke during a conference presentation. In a statement released before his presentation, Pujar noted that the life sciences are in “the age of information molecules.
Yet, enormous technological challenges in the delivery, cargo design, and manufacturing of these molecules have hindered the speedy and full realization of their potential.” “We created Mirai to solve these key limitations through AI trained on high quantities of quality in vivo data. By applying machine intelligence to the design of every atom within the medicine and opening this platform to the entire industry, we will have vast collective data points rolling through our optimization loops, allowing a greater innovation advantage to benefit each partner on the Mirai platform.
” Mirai’s machine intelligence-based, open platform uses proprietary data algorithms to unlock delivery to any tissue and cell type, optimize cargo design, and facilitate manufacturing, accelerating genetic medicines toward successful clinical translation for the company’s partners, continued Pujar, adding th.
